Blogs European Medtech Companies: Why a U.S. Centric Patent Strategy is Essential for Long-Term Success As European medtech companies look to expand their presence in the U.S. market, understanding the…Shabbi KhanNovember 12, 2024
Events TED AI 2024 October 23, 2024 | 9:00 a.m. PT | San Francisco, CA Foley & Lardner has…Natasha AllenSeptember 30, 2024
News Foley Represents Brazilian Health Care Startup Mevo in $19M Series B Funding Round Foley & Lardner LLP represented Mevo, a Brazilian health care startup, in its $19 million…Andre ThiollierSeptember 19, 2024
News Foley Represents TCGX as Lead Investor in $105M Series B Financing for Pathalys Pharma Foley & Lardner LLP represented TCG Crossover (TCGX) as the lead investor in the $105…Louis LehotSeptember 17, 2024
News Foley Represents ARCHIMED in Acquisition of Irrimax Corporation Foley & Lardner LLP recently represented global private equity health care specialist ARCHIMED in its…Brandee DiamondSeptember 3, 2024
Blogs An M&A Rebound? A Look at Q2 2024 Data We have all been waiting, some of us not…Louis LehotAugust 14, 2024
Blogs A Look at the Current State of Funding for Digital Health As we look back at the data from Q2, digital health is a mixed bag.…Louis LehotJuly 31, 2024
Blogs Vermont Governor Vetoes Data Privacy Act Following the Vermont Senate’s failure to override Governor Phil Scott’s veto of the Vermont Data…Jennifer HennessyJune 20, 2024
News Foley Represents TCGX in $30M Private Placement Financing in Nektar Therapeutics Foley & Lardner LLP represented TCG Crossover (“TCGX”) in the $30 million private placement financing…Louis LehotApril 12, 2024
News Foley Represents ARCHIMED in Acquisition of Majority Stake in Innovative Skincare Company Cellese Foley & Lardner LLP represented global private equity health care specialist ARCHIMED in its acquisition…Thomas CarlucciApril 11, 2024